DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.

Pompe disease is a rare genetic disorder that’s caused by the body’s inability to break down glycogen, a stored form of glucose, which is the body’s main form of energy. Normally ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

We report the safety and efficacy results of in utero enzyme-replacement therapy (ERT) in a fetus with CRIM (cross-reactive immunologic material)–negative infantile-onset Pompe’s disease.

t's important for children with Pompe disease to receive early and ongoing medical care to help manage their condition and improve their quality of life. International Pompe Day falls in April ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Pompe Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...

For effective management of these infants, it is critical that all potential causes are examined as early in the course of disease as possible. Pompe disease, also known as glycogen storage ...

The French pharmaceutical giant already markets Lumizyme and Nexviazyme for the disorder, called Pompe disease. Until this year, they were the only available Pompe treatments. In an administrative ...